The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

被引:7
|
作者
Jamous, Yahya F. [1 ]
Alhomoud, Dalal A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol, Natl Ctr Vaccine & Bioproc, Riyadh, Saudi Arabia
关键词
safety; efficacy; vaccines; mrna; sars-cov-2; COVID-19; VACCINE; HYPERSENSITIVITY; OUTCOMES; SEX;
D O I
10.7759/cureus.45602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and PfizerBioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
    Bettini, Emily
    Locci, Michela
    VACCINES, 2021, 9 (02) : 1 - 20
  • [32] mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
    Changhua Yi
    Yongxiang Yi
    Junwei Li
    Virologica Sinica, 2020, 35 (03) : 259 - 262
  • [33] mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
    Changhua Yi
    Yongxiang Yi
    Junwei Li
    Virologica Sinica, 2020, (03) : 259 - 262
  • [34] Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
    Fattizzo, Bruno
    Bortolotti, Marta
    Rampi, Nicolo
    Cavallaro, Francesca
    Giannotta, Juri Alessandro
    Bucelli, Cristina
    Cassin, Ramona
    Da Via, Matteo Claudio
    Galassi, Giulia
    Noto, Alessandro
    Pettine, Loredana
    Rossi, Francesca Gaia
    Sciume, Mariarita
    Ceriotti, Ferruccio
    Consonni, Dario
    Barcellini, Wilma
    Baldini, Luca
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Inserra, Felipe
    Tajer, Carlos
    Antonietti, Laura
    Mariani, Javier
    Ferder, Leon
    Manucha, Walter
    VACCINE, 2021, 39 (35) : 4930 - 4931
  • [36] Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
    John, Binu
    Ferreira, Raphaella
    Bastaich, Dustin
    Doshi, Akash
    Taddei, Tamar H.
    Kaplan, David
    Spector, Seth
    Dahman, Bassam
    JOURNAL OF HEPATOLOGY, 2022, 77 : S227 - S227
  • [37] Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
    Connolly, Caoilfhionn M.
    Ruddy, Jake A.
    Boyarsky, Brian J.
    Avery, Robin K.
    Werbel, William A.
    Segev, Dorry L.
    Garonzik-Wang, Jacqueline
    Paik, Julie J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (08) : 1100 - 1101
  • [38] Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes
    D'Addio, Francesca
    Sabiu, Gianmarco
    Usuelli, Vera
    Assi, Emma
    Abdelsalam, Ahmed
    Maestroni, Anna
    Seelam, Andy Joe
    Ben Nasr, Moufida
    Loretelli, Cristian
    Mileto, Davide
    Rossi, Giada
    Pastore, Ida
    Montefusco, Laura
    Morpurgo, Paola S.
    Plebani, Laura
    Rossi, Antonio
    Chebat, Enrica
    Bolla, Andrea M.
    Lunati, Maria Elena
    Mameli, Chiara
    Macedoni, Maddalena
    Antinori, Spinello
    Rusconi, Stefano
    Gallieni, Maurizio
    Berra, Cesare
    Folli, Franco
    Galli, Massimo
    Gismondo, Maria Rita
    Zuccotti, Gianvincenzo
    Fiorina, Paolo
    DIABETES, 2022, 71 (08) : 1800 - 1806
  • [39] Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
    Salleh, Mohd Zulkifli
    Norazmi, Mohd Nor
    Deris, Zakuan Zainy
    PEERJ, 2022, 10
  • [40] SARS-CoV-2 Vaccines
    Creech, C. Buddy
    Walker, Shannon C.
    Samuels, Robert J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (13): : 1318 - 1320